Literature DB >> 21886575

Gastrodia elata bl attenuates methamphetamine-induced dopaminergic toxicity via inhibiting oxidative burdens.

E-J Shin1, J-H Bach, T-T L Nguyen, X-K T Nguyen, B-D Jung, K-W Oh, M J Kim, S K Ko, C G Jang, S F Ali, H-C Kim.   

Abstract

It has been recognized that Gastrodia elata Bl (GE), an oriental herb medicine, ameliorates various neurological disorders, that GE modulates the monoaminergic and GABAergic systems, and that GE possess antioxidant activities. We examined whether GE affects methamphetamine (MA)-induced striatal dopaminergic toxicity in mice. Treatment with MA (7.5 mg/kg, i.p. × 4) resulted in significant decreases in behavioural activity (as shown by locomotor activity and rota rod performance), dopamine level, tyrosine hydroxylase (TH) activity, and TH protein expression (as evaluated by immunocytochemistry and western blot analysis). In addition, MA treatment showed significant increases in lipid peroxidation [as evaluated by 4-hydroxy-2-nonenal (4-HNE) expression and malondialdehyde formation], protein oxidation (as shown by protein carbonyl expression and its formation), and reactive oxygen species (ROS) formation. Treatment with GE significantly attenuates MA-induced behavioural and dopaminergic impairments, and oxidative stresses in a dose-dependent manner. Our results suggest that GE treatment shows anti-dopaminergic effects in response to MA insult via, at least in part, inhibiting oxidative stresses in the striatum of the mice.

Entities:  

Keywords:  Gastrodia elata Bl; dopamine; methamphetamine; oxidative stress.

Year:  2011        PMID: 21886575      PMCID: PMC3137164          DOI: 10.2174/157015911795016967

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


INTRODUCTION

Gastrodia elata Bl (GE) is a well-known herb agent that has been used to treat headache, paralysis, migraine, and other neurological disorders in oriental countries for centuries [1]. Prolonged GE treatment significantly increased dopamine (DA) concentration and decreased DA turnover in the striatum of the rats, suggesting that GE modulates DA system in the rats [2]. Recently, we filed a patent (Korean PCT10-2010-0000818; “pharmaceutical compositions containing GE extract useful for Parkinson’s disease”) to extend neuropharmacological indication of GE. Earlier evidences suggest that GE exerts antioxidant activities, which are attributable to its components (i.e. hydroxybenzyl aclcohol, vanillyl alcohol, vanillin and hydroxybenzaldehyde), and that their antioxidant effect in vitro is more potent than that by melatonin [3]. Methamphetamine (MA) leads to long-lasting depletion of nigrostriatal DA [4, 5], which is associated with increased oxidative damage [4, 6-9]. It has been suggested that humans who abuse MA have an increased risk for the PD later in life [6, 10]. Thus, MA-induced dopaminergic toxicity has been considered to be one of the important models for PD [5, 11, 12]. The present study was designed to investigate the pharmacological activity of GE on dopaminergic neurons to MA toxicity in mice. We evaluated the effects of GE on the dopaminergic impairments and oxidative stresses [i.e., lipid peroxidation and protein oxidation, and reactive oxygen species (ROS)] induced by MA.

METHODS

All animals were treated in accordance with the NIH Guide for the care and use of laboratory animals (NIH Publication No. 85-23, 1985; www.dels.nas.edu/ila). This study was performed in accordance with the Institute for Laboratory Animal Research (ILAR) guidelines for the care and use of laboratory animals. Male C57BL/6J mice (Bio Genomic Inc., Charles River Technology, Gapyung-Gun, Gyeonggi-Do, South Korea) weighing 25 ± 3 g were maintained on a 12 h:12 h light:dark cycle and fed ad libitum. MA was obtained from Korea Food & Drug Administration (KFDA) and dissolved in 0.9% sterile saline. Methanol extract of GE was obtained from Samsung Herb Medicine, Co. (Chunchon, South Korea) and suspended in 0.5 % carboxymethylcellulose. All solutions were immediately prepared before use. Experimental schedules in detail are shown in Fig. (). Locomotor activity and rota-rod performance were measured as described previously [13]. Striatal dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanilic acid (HVA), and TH activity were measured by HPLC-electrochemical detection [13, 14]. Dopamine turnover rate was calculated by the ratio of [(DOPAC + HVA)/ dopamine]. TH expression in the striatum was examined by western blot or immunocytochemical analyses [13] using primary antibody against TH (1:5,000, Chemicon, Temecula, MA, USA) or β-actin (1:50,000, Sigma-Aldrich, St Louis, MO, USA). Protein oxidation was measured by slot blot analysis [13] using Oxyblot kit (Chemicon, Temecula, MA, USA) or by spectrophotometrical determination using 2,4-dinitro-phenylhydrazine (DNPH)-labeling procedure [13]. Lipid peroxidation was determined by slot blot analysis using primary antibody against 4-hydroxy-2-nonenal (4-HNE) (Calbiochem, Gibbstown, NJ, USA) [13] or by HPLC-UV/VIS detection of malondialdehyde [13]. Synaptosomal reactive oxygen species (ROS) was measured as described previously [15]. Striatal synaptosomes from four animals pooled for each assay. Statistical analyses were performed using one-way analysis of variance (ANOVA) or repeated measure one-way ANOVA. A post-hoc Fisher’s PLSD test was then applied. A p value < 0.05 was deemed to indicate statistical significance.

RESULTS AND DISCUSSION

Experimental protocol for this study was shown in Fig. (). Mice receiving GE (500 or 1000 mg/kg, p.o.) alone did not show any specific behaviours. Three days after final MA treatment, mice showed significant decreased locomotor activity (p < 0.01 vs. Saline) and rota rod performance (p < 0.01 vs. Saline) (Fig. and ). Representative locomotor tracing patterns also support respective locomotor activity (Fig. ). GE treatment attenuated these behavioural impairments (Locomotor activity and Rota rod performance; Saline + MA vs. GE 500 or 1000 mg/kg + MA, p < 0.05) (Fig. and ). MA treatment significantly decreased dopamine levels (p < 0.01 vs. Saline), while dopamine turnover rate was significantly increased (p < 0.01 vs. Saline). GE treatment significantly attenuated changes in dopamine levels (Saline + MA vs. GE 500 or 1000 mg/kg + MA, p < 0.05) and dopamine turnover rate (Saline + MA vs. GE 500 mg/kg + MA or GE 1000mg/kg + MA, p < 0.05) and induced by MA (Fig. and ). In this study, changes in tyrosine hydroxylase (TH) activity are in line with those in TH expression (as shown by immunocytochemistry and western blot analysis). Consistently, tendency of TH activity and TH expressions apparently is in line with that of dopamine levels (Fig. and ). Fig. (). showed the changes in the lipid peroxidation (as shown by 4-HNE expression and MDA level), protein oxidation (as shown by protein carbonyl expression and protein carbonyl level) and ROS. A mild expression of 4-HNE was observed in saline- or GE-treatment. MA significantly increased 4-HNE expression (p < 0.01 vs. Saline). The result in 4-HNE expression was consistent with that in MDA level. A mild to moderate expression of protein carbonyl was noted in the saline or GE-treated group. Similar to 4-HNE, MA treatment significantly increased (p < 0.01 vs. Saline) protein carbonyl expression and its level. In addition, formations of ROS are apparently in line with those of MDA and protein carbonyl. GE treatment was significantly inhibited these markers of oxidative stress [expressions of HNE and protein carbonyl, and formations of MDA, protein carbonyl and ROS: Sal + MA vs. GE (500 mg/kg or 1000 mg/kg) + MA, p < 0.05]. In the present study, we showed that GE significantly attenuates MA-induced impairments in the behavioural activity, dopaminergic function, and that GE significantly inhibited MA-induced pathologic oxidative changes. Therefore, our results indicate that GE-mediated antioxidant effects may contribute to block MA-induced dopaminergic toxicity in mice. To our knowledge, this is the first time that GE attenuates dopaminergic toxicity. Major components of GE are vanillyl alcohol, phenolic compounds, organic acids, glucose, beta-sitosterol, hydroxybenzyl alcohol, vanillin, gastrodin and hydroxybenzaldehyde [16]. Vanillyl alcohol showed antioxidant effects in response to excitotoxic condition in rats [17]. Gastrodin was reported to increase the GABA level by inhibiting the GABA shunt [18]. Recently, it was suggested that the order of antioxidant potency of components of GE is hydroxylbenzyl alcohol > vanillyl alcohol > vanillin > hydroxybenzaldehyde [3]. Correspondingly, Liu and Mori [19] demonstrated that GE inhibits cerebral lipid peroxidation via in part modulating antioxidant enzymes. Many evidence indicated that GE mainly modulates GABAergic system, although GE also modulates dopaminergic and serotonergic systems. Earlier study demonstrated that high-dose MA enhances dopamine D1 receptor-mediated nigrostriatal GABAergic transmission, which activates GABAA receptors in the substantia nigra, leading to a decrease in GABAergic nigrothalamic activity, and increase in corticostriatal glutamate release, and a consequent long-term depeletion of striatal dopamine contents [20]. This finding may be associated with increased formation of free radical [7]. This increase in free radical formation consequently results in increases in markers of lipid peroxidation and protein oxidation, namely MDA/4HNE and protein carbonyl as shown in this study. Thus, we raise the possibility that GABAergic effects of GE may be, at least in part, important for GE-mediated neuroprotection. We observed in our pilot study that anti-dopaminergic effects of GE are more pronounced than those of respective component of GE and the dose less than 500 mg/kg GE is not effective in preventing MA toxicity (data not shown). In addition, it remains to be fully determined on the interaction between GABAergic, dopaminergic populations and antioxidant components after exposed to GE. Combined, we indicate that antioxidant properties of GE may be helpful for treatment of oxidative stress responsible neurological disorders, although it’s precise mechanism remains elusive.
  20 in total

1.  Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation.

Authors:  S Z Imam; S F Ali
Journal:  Brain Res       Date:  2000-02-07       Impact factor: 3.252

2.  Antioxidant and free radical scavenging activities of Gastrodia elata Bl. and Uncaria rhynchophylla (Miq.) Jacks.

Authors:  J Liu; A Mori
Journal:  Neuropharmacology       Date:  1992-12       Impact factor: 5.250

3.  Protection of methamphetamine nigrostriatal toxicity by dietary selenium.

Authors:  H C Kim; W K Jhoo; D Y Choi; D H Im; E J Shin; J H Suh; R A Floyd; G Bing
Journal:  Brain Res       Date:  1999-12-18       Impact factor: 3.252

4.  Anticonvulsive and free radical scavenging activities of vanillyl alcohol in ferric chloride-induced epileptic seizures in Sprague-Dawley rats.

Authors:  C L Hsieh; C H Chang; S Y Chiang; T C Li; N Y Tang; C Z Pon; C T Hsieh; J G Lin
Journal:  Life Sci       Date:  2000       Impact factor: 5.037

5.  Isolation and identification of succinic semialdehyde dehydrogenase inhibitory compound from the rhizome of Gastrodia elata Blume.

Authors:  N I Baek; S Y Choi; J K Park; S W Cho; E M Ahn; S G Jeon; B R Lee; J H Bahn; Y K Kim; I H Shon
Journal:  Arch Pharm Res       Date:  1999-04       Impact factor: 4.946

6.  High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity.

Authors:  Karla A Mark; Jean-Jacques Soghomonian; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

7.  Treatment of mice with methamphetamine produces cell loss in the substantia nigra.

Authors:  P K Sonsalla; N D Jochnowitz; G D Zeevalk; J A Oostveen; E D Hall
Journal:  Brain Res       Date:  1996-10-28       Impact factor: 3.252

8.  Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine.

Authors:  A Giovanni; L P Liang; T G Hastings; M J Zigmond
Journal:  J Neurochem       Date:  1995-04       Impact factor: 5.372

Review 9.  [Recent progress on pharmacological effects of Gastrodia elata].

Authors:  Yun-Hai Tao
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2008-01

10.  Gastrodin decreases immunoreactivities of gamma-aminobutyric acid shunt enzymes in the hippocampus of seizure-sensitive gerbils.

Authors:  Sung-Jin An; Seung-Kook Park; In Koo Hwang; Soo Young Choi; Sang Kook Kim; Oh-Shin Kwon; Sung Je Jung; Nam-In Baek; Hyeon Yong Lee; Moo Ho Won; Tae-Cheon Kang
Journal:  J Neurosci Res       Date:  2003-02-15       Impact factor: 4.164

View more
  9 in total

1.  Neuroprotective effect of aqueous extract of Selaginella delicatula as evidenced by abrogation of rotenone-induced motor deficits, oxidative dysfunctions, and neurotoxicity in mice.

Authors:  Girish Chandran
Journal:  Cell Mol Neurobiol       Date:  2013-07-19       Impact factor: 5.046

2.  Gastrodin ameliorates memory deficits in 3,3'-iminodipropionitrile-induced rats: possible involvement of dopaminergic system.

Authors:  Xiaona Wang; Shaofeng Yan; Aiqin Wang; Yanli Li; Feng Zhang
Journal:  Neurochem Res       Date:  2014-05-20       Impact factor: 3.996

3.  L-Ascorbate Protects Against Methamphetamine-Induced Neurotoxicity of Cortical Cells via Inhibiting Oxidative Stress, Autophagy, and Apoptosis.

Authors:  Ya-Ni Huang; Ling-Yu Yang; Jing-Ya Wang; Chien-Cheng Lai; Chien-Tsai Chiu; Jia-Yi Wang
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

4.  20C, a bibenzyl compound isolated from Gastrodia elata, protects PC12 cells against rotenone-induced apoptosis via activation of the Nrf2/ARE/HO-1 signaling pathway.

Authors:  Ju-Yang Huang; Yu-He Yuan; Jia-Qing Yan; Ya-Nan Wang; Shi-Feng Chu; Cheng-Gen Zhu; Qing-Lan Guo; Jian-Gong Shi; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

5.  The Aqueous Extract of Rhizome of Gastrodia elata Protected Drosophila and PC12 Cells against Beta-Amyloid-Induced Neurotoxicity.

Authors:  Chun-Fai Ng; Chun-Hay Ko; Chi-Man Koon; Jia-Wen Xian; Ping-Chung Leung; Kwok-Pui Fung; Ho Yin Edwin Chan; Clara Bik-San Lau
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-23       Impact factor: 2.629

Review 6.  Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson's disease.

Authors:  Sushruta Koppula; Hemant Kumar; Sandeep Vasant More; Hyung-Woo Lim; Soon-Min Hong; Dong-Kug Choi
Journal:  Molecules       Date:  2012-09-26       Impact factor: 4.411

7.  Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy?

Authors:  Sven Schröder; Kathrin Beckmann; Giovanna Franconi; Gesa Meyer-Hamme; Thomas Friedemann; Henry Johannes Greten; Matthias Rostock; Thomas Efferth
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-31       Impact factor: 2.629

Review 8.  The Role of Oxidative Stress in Methamphetamine-induced Toxicity and Sources of Variation in the Design of Animal Studies.

Authors:  Kate McDonnell-Dowling; John P Kelly
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 9.  Natural Products in Modulating Methamphetamine-Induced Neuronal Apoptosis.

Authors:  Yiwei Zeng; Yunhui Chen; Su Zhang; Huan Ren; Jialin Xia; Mengnan Liu; Baozhi Shan; Yulan Ren
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.